GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » EV-to-EBIT

SNY (Sanofi) EV-to-EBIT : 21.88 (As of Oct. 31, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sanofi EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sanofi's Enterprise Value is $151,359 Mil. Sanofi's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $6,919 Mil. Therefore, Sanofi's EV-to-EBIT for today is 21.88.

The historical rank and industry rank for Sanofi's EV-to-EBIT or its related term are showing as below:

SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.5   Med: 17.12   Max: 41.63
Current: 21.71

During the past 13 years, the highest EV-to-EBIT of Sanofi was 41.63. The lowest was 7.50. And the median was 17.12.

SNY's EV-to-EBIT is ranked worse than
61.56% of 666 companies
in the Drug Manufacturers industry
Industry Median: 17.615 vs SNY: 21.71

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sanofi's Enterprise Value for the quarter that ended in Jun. 2024 was $139,982 Mil. Sanofi's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $6,919 Mil. Sanofi's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 4.94%.


Sanofi EV-to-EBIT Historical Data

The historical data trend for Sanofi's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi EV-to-EBIT Chart

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.79 7.71 14.90 11.16 15.63

Sanofi Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 11.16 - 15.63 -

Competitive Comparison of Sanofi's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Sanofi's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sanofi's EV-to-EBIT falls into.



Sanofi EV-to-EBIT Calculation

Sanofi's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=151358.894/6918.875
=21.88

Sanofi's current Enterprise Value is $151,359 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $6,919 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi  (NAS:SNY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sanofi's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=6918.875/139982.2982
=4.94 %

Sanofi's Enterprise Value for the quarter that ended in Jun. 2024 was $139,982 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanofi's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $6,919 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanofi EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sanofi's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi Business Description

Address
46, avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines

From GuruFocus

Q2 2023 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Sanofi SA at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 02-09-2024

Sanofi SA at TD Cowen Health Care Conference Transcript

By GuruFocus Research 03-25-2024

Q3 2022 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Sanofi SA Annual Shareholders Meeting (French) Transcript

By GuruFocus Research 02-09-2024

Sanofi SA ATS Investor Call Transcript

By GuruFocus Research 02-09-2024

Sanofi SA's Dividend Analysis

By GuruFocus Research 05-08-2024